Research Article
Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
Table 2
Efficacy total, by primary regimen including on schedule/discont, by rescue regimen, by GT, and by fibrosis.
| | | ITT, n (%) | mITT, n (%) | | | completed primary therapy | discontinued primary therapy | completed primary therapy | discontinued primary therapy |
| | by primary regimen | | | | | | OBV/PTV/r+DSV ± RBV | 3/4 (75%) | 10/11 (91%) | 3/4 (75%) | 10/10 (100%) | | LDV/SOF ± RBV | 4/7 (57%) | 0 | 4/6 (67%) | 0 | | other SOF based | 5/5 (100%) | 0 | 5/5 (100%) | 0 | | ASV+DCV | 2/3 (67%) | 1/1 (100%) | 2/3 (67%) | 1/1 (100%) |
| | by rescue regimen | | | | | | OBV/PTV/r ± DSV ± RBV | 3/4 (75%) | 1/1 (100%) | 3/4 (75%) | 1/1 (100%) | | LDV/SOF ± RBV | 6/8 (75%) | 10/11 (91%) | 6/8 (75%) | 10/10 (100%) | | GZR/EBR | 2/3 (67%) | 0 | 2/2 (100%) | 0 | | SOF+DCV ± RBV | 2/3 (67%) | 0 | 2/3 (67%) | 0 |
| | by genotype | | | | | | 1b | 9/12 (75%) | 10/11 (91%) | 9/12 (75%) | 10/10 (100%) | | 3 | 2/3 (67%) | 0 | 2/3 (67%) | 0 | | 4 | 3/4 (75%) | 1/1 (100%) | 3/3 (100%) | 1/1 (100%) |
| | by fibrosis | | | | | | non-cirrhotics | 6/6 (100%) | 3/3 (100%) | 6/6 (100%) | 3/3 (100%) | | cirrhotics | 8/13 (62%) | 8/9 (89%) | 8/12 (67%) | 8/8 (100%) |
|
|
GT: genotype; ITT: intent-to-treat; mITT: modified intent-to-treat; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir; GZR: grazoprevir; EBR: elbasvir.
|
